The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

Tamiem Adam; Therese M. Becker; Wei Chua; Victoria Bray; Tara L. Roberts

doi:10.3390/cancers13020277

The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

Tamiem Adam, Therese M. Becker, Wei Chua, Victoria Bray, Tara L. Roberts

Western Sydney University

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

Original language	English
Article number	277
Number of pages	20
Journal	Cancers
Volume	13
Issue number	2
DOIs	https://doi.org/10.3390/cancers13020277
Publication status	Published - 2021

Open Access - Access Right Statement

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Keywords

biochemical markers
cancer
immunotherapy
melanoma
renal cell carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13020277

Cite this

@article{309bc5bf2c104d38ac5c354b3822b74a,

title = "The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack",

abstract = "Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.",

keywords = "biochemical markers, cancer, immunotherapy, melanoma, renal cell carcinoma",

author = "Tamiem Adam and Becker, {Therese M.} and Wei Chua and Victoria Bray and Roberts, {Tara L.}",

year = "2021",

doi = "10.3390/cancers13020277",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

AU - Adam, Tamiem

AU - Becker, Therese M.

AU - Chua, Wei

AU - Bray, Victoria

AU - Roberts, Tara L.

PY - 2021

Y1 - 2021

N2 - Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

AB - Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

KW - biochemical markers

KW - cancer

KW - immunotherapy

KW - melanoma

KW - renal cell carcinoma

UR - http://hdl.handle.net/1959.7/uws:58573

U2 - 10.3390/cancers13020277

DO - 10.3390/cancers13020277

M3 - Article

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 2

M1 - 277

ER -

The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

Abstract

Open Access - Access Right Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this